Serum levels and mutual correlations of amyloid β in patients with depression.
amyloid β
depression
major depressive disorder
oligomer
serum
Journal
Geriatrics & gerontology international
ISSN: 1447-0594
Titre abrégé: Geriatr Gerontol Int
Pays: Japan
ID NLM: 101135738
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
11
07
2019
revised:
09
10
2019
accepted:
11
11
2019
pubmed:
14
12
2019
medline:
9
6
2020
entrez:
14
12
2019
Statut:
ppublish
Résumé
Epidemiological studies have shown that depression is a risk factor for Alzheimer's disease (AD). Although the biological mechanism underlying the link between depression and AD is unclear, altered amyloid β (Aβ) metabolism in patients with depression has been suggested as a potential mechanism. Results from previous studies of Aβ metabolism in patients with depression have been inconsistent, and Aβ polymerization, which is a crucial process in AD pathology, has not previously been assessed. Serum levels of Aβ40, Aβ42 and Aβ oligomers were evaluated in 104 inpatients with major depressive disorder (MDD) and 132 healthy control individuals. Lower serum Aβ42 levels were observed in patients with MDD, but there was no difference in serum Aβ oligomer levels between the MDD group and the healthy control group, even in older adults. Interestingly, serum Aβ oligomer levels in patients with MDD were dependent on serum Aβ42 levels, regardless of age, and this relationship was not observed in the control group. These results suggest that Aβ42 is more prone to aggregation and polymerization in patients with depression than in healthy individuals, suggesting a possible mechanism underlying the transition from depression to AD. Geriatr Gerontol Int 2020; 20: 125-129.
Substances chimiques
Amyloid beta-Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-129Subventions
Organisme : Juntendo Institute of Mental Health
Organisme : AMED
ID : JP18dk0307060
Informations de copyright
© 2019 Japan Geriatrics Society.
Références
Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol 2011; 7: 323-331.
da Silva J, Goncalves-Pereira M, Xavier M, Mukaetova-Ladinska EB. Affective disorders and risk of developing dementia: systematic review. Br J Psychiatry 2013; 202: 177-186.
Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry 2013; 202: 329-335.
Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 2008; 70: 1258-1264.
Bateman RJ, Xiong C, Benzinger TL et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001; 21: 372-381.
Lopez OL, Kuller LH, Mehta PD et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 2008; 70: 1664-1671.
Nakamura A, Kaneko N, Villemagne VL et al. High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature 2018; 554: 249-254.
van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006; 5: 655-660.
Graff-Radford NR, Crook JE, Lucas J et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64: 354-362.
Nascimento KK, Silva KP, Malloy-Diniz LF, Butters MA, Diniz BS. Plasma and cerebrospinal fluid amyloid-beta levels in late-life depression: a systematic review and meta-analysis. J Psychiatr Res 2015; 69: 35-41.
Pomara N, Doraiswamy PM, Willoughby LM et al. Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res 2006; 31: 341-349.
Sun X, Mwamburi DM, Bungay K et al. Depression, antidepressants, and plasma amyloid beta (Beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry 2007; 62: 1413-1417.
Namekawa Y, Baba H, Maeshima H et al. Heterogeneity of elderly depression: increased risk of Alzheimer's disease and Abeta protein metabolism. Prog Neuropsychopharmacol Biol Psychiatry 2013; 43: 203-208.
Baba H, Nakano Y, Maeshima H et al. Metabolism of amyloid-beta protein may be affected in depression. J Clin Psychiatry 2012; 73: 115-120.
Eto M, Watanabe K, Ishii K. A rapid flat gel isoelectric focusing method for the determination of apolipoprotein E phenotypes and its application. Clin Chim Acta 1985; 149: 21-28.
Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT. A Luminex assay detects amyloid beta oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One 2013; 8: e67898.
Savage MJ, Kalinina J, Wolfe A et al. A sensitive abeta oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. J Neurosci 2014; 34: 2884-2897.
Jongbloed W, Bruggink KA, Kester MI et al. Amyloid-beta oligomers relate to cognitive decline in Alzheimer's disease. J Alzheimers Dis 2015; 45: 35-43.
Yang T, O'Malley TT, Kanmert D et al. A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res Ther 2015; 7: 14.
Schuster J, Funke SA. Methods for the specific detection and quantitation of amyloid-beta oligomers in cerebrospinal fluid. J Alzheimers Dis 2016; 53: 53-67.
Santos AN, Simm A, Holthoff V, Boehm G. A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with flow cytometry and its application in the diagnostics of Alzheimer's disease. J Alzheimers Dis 2008; 14: 127-131.
Xia W, Yang T, Shankar G et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 2009; 66: 190-199.
Zhou L, Chan KH, Chu LW et al. Plasma amyloid-beta oligomers level is a biomarker for Alzheimer's disease diagnosis. Biochem Biophys Res Commun 2012; 423: 697-702.
Toledo JB, Toledo E, Weiner MW et al. Cardiovascular risk factors, cortisol, and amyloid-beta deposition in Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2012; 8: 483-489.
Sehlin D, Sollvander S, Paulie S et al. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J Alzheimers Dis 2010; 21: 1295-1301.
Donner L, Gremer L, Ziehm T et al. Relevance of N-terminal residues for amyloid-beta binding to platelet integrin alphaIIbbeta3, integrin outside-in signaling and amyloid-beta fibril formation. Cell Signal 2018; 50: 121-130.
Abdullah L, Paris D, Luis C et al. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett 2007; 428: 53-58.
Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009; 61: 89-104.
Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 2010; 626: 64-71.